Haystack oncology and lisata therapeutics initiate research collaboration to use the haystack mrd™ technology to evaluate efficacy of pancreatic cancer therapy

Baltimore, md. and basking ridge, n.j., july 18, 2024 (globe newswire) -- haystack oncology, a quest diagnostics (nyse: dgx) company, and lisata therapeutics, inc. (nasdaq: lsta), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced a research collaboration. lisata will deploy the highly sensitive haystack mrd™ technology for the detection of circulating tumor dna (ctdna) in a clinical study evaluating certepetide plus chemotherapy as an investigational treatment for metastatic pancreatic cancer.
DGX Ratings Summary
DGX Quant Ranking